Update on Peripheral Nerve Sheath Tumors

Anthony P Martinez; Karen J Fritchie

doi:10.1016/j.path.2018.10.001

Update on Peripheral Nerve Sheath Tumors

Surg Pathol Clin. 2019 Mar;12(1):1-19. doi: 10.1016/j.path.2018.10.001. Epub 2018 Dec 17.

Authors

Anthony P Martinez¹, Karen J Fritchie²

Affiliations

¹ Department of Laboratory Medicine and Pathology, Mayo Clinic, 200 First Street Southwest, Rochester, MN 55905, USA.
² Department of Laboratory Medicine and Pathology, Mayo Clinic, 200 First Street Southwest, Rochester, MN 55905, USA. Electronic address: fritchie.karen@mayo.edu.

PMID: 30709438
DOI: 10.1016/j.path.2018.10.001

Abstract

Recent work has revealed SMARCB1/INI1 loss by immunohistochemistry in a subset of epithelioid schwannomas and explored the significance of cytologic atypia and increased mitotic activity in these tumors. Additional studies have evaluated the utility and limitations of histone H3K27 trimethylation in diagnosis of high-grade and low-grade malignant peripheral nerve sheath tumors. New terminology regarding nerve sheath tumors in neurofibromatosis type 1 patients was proposed during a 2016 conference to better define guidelines for classification of this group of tumors. This review highlights novel findings and practical applications relating to these topics in peripheral nerve sheath tumors.

Keywords: Epithelioid schwannoma; H3K27me3; Nerve sheath tumors; SMARCB1/INI1.

Publication types

Review

MeSH terms

Biomarkers, Tumor / genetics
DNA Methylation
Diagnosis, Differential
Histones / metabolism
Humans
Immunohistochemistry
Nerve Sheath Neoplasms* / classification
Nerve Sheath Neoplasms* / diagnosis
Nerve Sheath Neoplasms* / genetics
Nerve Sheath Neoplasms* / pathology
Prognosis
Terminology as Topic

Substances

Biomarkers, Tumor
Histones